Two centuries of assessing drug risks.
Harvard Medical School and the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, USA.
Jerry
J
Avorn
D016208:Databases, Factual; D004341:Drug Evaluation / Q000266:history* / Q000379:methods; D004358:Drug Therapy / Q000266:history*; D004335:Drug and Narcotic Control / Q000266:history*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000266:history*; D005026:Ethylene Glycols / Q000266:history / Q000506:poisoning; D049672:History, 19th Century; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000266:history; D004364:Pharmaceutical Preparations / Q000266:history; D000077154:Rosiglitazone; D000077145:Sulfanilamide; D013424:Sulfanilamides / Q000266:history; D013450:Sulfones / Q000009:adverse effects / Q000266:history; D045162:Thiazolidinediones / Q000009:adverse effects / Q000266:history; D014481:United States; D014486:United States Food and Drug Administration / Q000266:history*
D005026:Ethylene Glycols; D007783:Lactones; D004364:Pharmaceutical Preparations; D013424:Sulfanilamides; D013450:Sulfones; D045162:Thiazolidinediones; D000077154:Rosiglitazone; C116926:rofecoxib; D000077145:Sulfanilamide; C013484:diethylene glycol